Imatinib

About

Therapy type: Targeted therapy

Therapy strategy: Bcr-Abl inhibition, c-Kit inhibition, PDGF-R inhibition

Mappings

NCI Thesaurus: Imatinib (ncit:C62035)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	FDA
Sensitivity (+)	PDGFRA rearrangements	Myelodysplastic Syndromes	Imatinib	FDA
Sensitivity (+)	PDGFRB rearrangements	Myelodysplastic Syndromes	Imatinib	FDA
Sensitivity (+)	KIT p.D816V	Aggressive Systemic Mastocytosis	Imatinib	FDA
Sensitivity (+)	FIP1L1::PDGFRA	Chronic Eosinophilic Leukemia, NOS	Imatinib	FDA
Sensitivity (+)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib	FDA
Sensitivity (+)	FIP1L1::PDGFRA	Gastrointestinal Stromal Tumor	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	HC
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	HC
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	HC
Sensitivity (+)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib	HC
Sensitivity (+)	PDGFRA rearrangements	Myelodysplastic Syndromes	Imatinib	HC
Sensitivity (+)	PDGFRB rearrangements	Myelodysplastic Syndromes	Imatinib	HC
Sensitivity (+)	PDGFRA rearrangements	Myeloproliferative Neoplasm	Imatinib	HC
Sensitivity (+)	PDGFRB rearrangements	Myeloproliferative Neoplasm	Imatinib	HC
Sensitivity (+)	KIT p.D816V	Aggressive Systemic Mastocytosis	Imatinib	HC
Sensitivity (+)	FIP1L1::PDGFRA	Chronic Eosinophilic Leukemia, NOS	Imatinib	HC
Sensitivity (+)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib	HC
Sensitivity (+)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib	HC